A Phase 4 interventional study of Dexamethasone and Glucose Injection in Carpal Tunnel Syndrome, sponsored by Assiut University. Status unknown at 1 site in Egypt. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-08-11.
Sponsored by Assiut University · Phase 4, Interventional, and Treatment
To assess pain relief and quality of life among patients with carpal tunnel syndrome after local steroid vs. glucose 5% injection.
Carpal tunnel syndrome (CTS) is the most prevalent type of peripheral nerve entrapment involving compression of the median nerve in the carpal tunnel. 1 This condition is more common in females than in males. CTS may be unilateral or bilateral. It is a significant cause of morbidity and poor quality of life in those patients. There is deterioration in functional outcomes and maybe psychologically as well. The severity of CTS varied from mild to moderate to severe. Its signs and symptoms include numbness along with the median nerve distribution of the hand, pain, atrophy of muscles, handgrip weakness, etc. Mild or moderate cases are usually seeking conservative treatment like electrotherapeutic modalities, manual therapy interventions, oral supplements and medications, and wrist immobilizations such as splints. Severe cases are likely to go toward surgery. But most patients with CTS are reluctant to take the surgical choice, mainly because of financial issues and secondary complications. Therefore, the evaluation of the effectiveness of the non-surgical (conservative) therapies should be a major concern, as they are cost-effective and lacks secondary complications. Much research has been conducted to see the efficacy of various conservative therapies.
-study method: We are going to carry out a double-blinded randomized, case-controlled study on 52 patients who are randomly chosen and categorized them into 2 groups, 26 patients each. we planned to inject steroid( 4 mg of dexamethasone acetate combined with 1% lidocaine into the carpal tunnels) directly into the carpal tunnel in (group 1) and to inject 10 ml glucose 5% into the carpal tunnel for the other group (group 2).. All injections will be under sonographic guidance. Neurophysiology, U/S, pain scales, and quality of life scales studies will be performed for these two groups before treatment and after 12 weeks of injection. The patients will be followed up for 3 months.
605 studies on the registry are indexed under Carpal Tunnel Syndrome; 138 are open to participants now.
This study's planned enrollment of 52 is below the median of 60 across 457 interventional studies indexed under Carpal Tunnel Syndrome.
Browse Carpal Tunnel Syndrome studies →Assiut University is the lead sponsor of 5,050 studies on the registry; 2,174 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
26 patients we planned to inject them local steroid( 4 mg of dexamethasone acetate combined with 1% lidocaine into the carpal tunnels) directly into the carpal tunnel in (group A)
Drug: Dexamethasone · Drug: Glucose Injection
26 patients we planned to inject them local glucose 5% ( 10 ml glucose) directly into the carpal tunnel in (group A)
Drug: Dexamethasone · Drug: Glucose Injection
we planned to inject steroid( 4 mg of dexamethasone acetate combined with 1% lidocaine into the carpal tunnels) directly into the carpal tunnel in group A
inject10 ml glucose 5% into the carpal tunnel in group B
Also known as: glucose 5%
the changes in visual analogue scale (pre - post- and follow up)
the changes in visual analogue scale (pre - post- and follow up) Using a ruler, the score is determined by measuring the distance (mm) on the 10-cm line between the "no pain" anchor and the patient's mark, providing a range of scores from 0-100. A higher score indicates greater pain intensity. Based on the distribution of pain VAS scores . pain intensity described as none, mild, moderate, or severe, the following cut points on the pain VAS have been recommended: no pain (0-4 mm), mild pain(5-44 mm), moderate pain (45-74 mm), and severe pain (75-100 mm).
Time frame: 14 days
-To evaluate the effect of sonar guided steroid vs. glucose 5% injection on U/S (pre-post and follow up).
To evaluate the effect of sonar guided steroid vs. glucose 5% injection on U/S (pre-post and follow up). -U/S In the literature, four criteria are used to diagnose CTS by sonography: 1. Increase in cross-sectional area at the level of the pisiform bone; 2. Increase in the flattening ratio at the level of the hook of the Hamate 3. Palmar bowing of the flexor retinaculum by sonography. The above readings will be calculated and will be compared to the previous readings of the same patient of each group. eg. The grade of CTS severity was classified according to the CSA of the median nerve considering 10.0 - 12.9mm2 as mild grade, 13.0 - 15.0mm2 as moderate grade and \>15.0 mm2 as severe grade
Time frame: 3 months
To evaluate the effect of sonar guided steroid vs. glucose 5% injection on neurophysiological studies (pre-post and follow up).
To evaluate the effect of sonar guided steroid vs. glucose 5% injection on neurophysiological studies (pre-post and follow up). Neurophysiology studies (sensory, motor conduction, and f wave of both median and ulnar nerve) Grade ............................................ EDX Abnormality 1. Very mild CTS ............ .................. detected by only PWDSLD\* 2. Mild Median.................................... DML \<4.5 and sensory NCV \<40 3. Moderately severe Median............. DML♦ \>4.5 and \<6.5 with preserved SNAP 4. Severe Median ...............................DML \>4.5 and \<6.5 with absent SNAP 5. Very severe Median....................... DML \>6.5 with CMAP \>0.2 mv 6. Extremely severe Median ...............CMAP from APB \<0.2 mv we detect improvment in latency, amplitude and NCV after 3 months of local injection and comparing it with previous readings of the same patient of each group.
Time frame: 3 months
This study is status unknown, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Glucose